Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study-Reference-Cited by-同舟云学术

Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study

Published:2022-10 Issue:10 Volume:28 Page:1086-1095
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Basu Anirban¹²,Benson Carmela³,Turkoz Ibrahim⁴,Patel Charmi³,Baker Pamela³,Brown Brianne³

Affiliation:

1. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle.

2. Salutis Consulting LLC, Bellevue, WA.

3. Janssen Scientific Affairs, LLC, Titusville, NJ.

4. Janssen Research and Development, LLC, Titusville, NJ.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference19 articles.

1. Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden

2. The nature of relapse in schizophrenia

3. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study

4. The cost of relapse and the predictors of relapse in the treatment of schizophrenia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug delivery breakthrough technologies – A perspective on clinical and societal impact;Journal of Controlled Release;2023-08

2. Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia;Journal of Managed Care & Specialty Pharmacy;2023-03